Diabetes Care, Vol 18, Issue 11 1468-1478, Copyright © 1995 by American Diabetes Association

ARTICLES

Resource utilization and costs of care in the diabetes control and complications trial

OBJECTIVE: To describe in detail the resources used and costs incurred in the clinical management of patients with insulin-dependent diabetes mellitus (IDDM) in the Diabetes Control and Complications Trial (DCCT). RESEARCH DESIGN AND METHODS: The resources used for intensive and conventional therapy and to deal with the side effects of therapy were assessed at each of the 29 DCCT clinics and summarized. Unit costs were derived from the DCCT, manufacturers, and Medicare and chosen to reflect what an item would cost to a single-payer national health system. Costs were calculated as the product of resources used and unit costs. The costs of the research component of the DCCT were not included. RESULTS: In the DCCT, the annual cost of intensive therapy ($4,000 and $5,800/year for multiple daily injections and continuous subcutaneous insulin infusion, respectively) was approximately three times the cost of conventional therapy ($1,700/year). A large portion of the difference in cost was related to the greater frequency of outpatient visits and the greater resources used in self-care. CONCLUSIONS: DCCT intensive therapy is more expensive than conventional therapy, but it offers the hope of cost savings as a result of averted complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. R. Gambert and S. Pinkstaff Emerging Epidemic: Diabetes in Older Adults: Demography, Economic Impact, and Pathophysiology Diabetes Spectr, October 1, 2006; 19(4): 221 - 228. [Abstract] [Full Text] [PDF]

				D. P. Ritzwoller, D. Toobert, A. Sukhanova, and R. E. Glasgow Economic analysis of the mediterranean lifestyle program for postmenopausal women with diabetes. The Diabetes Educator, September 1, 2006; 32(5): 761 - 769. [Abstract] [Full Text] [PDF]

				A. M. Delamater Improving Patient Adherence Clin. Diabetes, April 1, 2006; 24(2): 71 - 77. [Abstract] [Full Text] [PDF]

				W. H. Herman, L. L. Ilag, S. L. Johnson, C. L. Martin, J. Sinding, A. Al Harthi, C. D. Plunkett, F. B. LaPorte, R. Burke, M. B. Brown, et al. A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes Diabetes Care, July 1, 2005; 28(7): 1568 - 1573. [Abstract] [Full Text] [PDF]

				S. A. Weinzimer, E. A. Doyle, and W. V. Tamborlane Jr Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies Clinical Pediatrics, June 1, 2005; 44(5): 393 - 403. [Abstract] [PDF]

				G. T. Mucha, S. Merkel, W. Thomas, and J. P. Bantle Fasting and Insulin Glargine in Individuals With Type 1 Diabetes Diabetes Care, May 1, 2004; 27(5): 1209 - 1210. [Full Text] [PDF]

				Intensive Diabetes Management: Implications of the DCCT and UKPDS The Diabetes Educator, September 1, 2002; 28(5): 735 - 740. [PDF]

				J. A. Sanfield, M. Hegstad, and R. S. Hanna Protocol for Outpatient Screening and Initiation of Continuous Subcutaneous Insulin Infusion Therapy: Impact on Cost and Quality The Diabetes Educator, July 1, 2002; 28(4): 599 - 607. [Abstract] [PDF]

				G. L. Booth, B. Zinman, and D. A. Redelmeier Diabetes Care in the U.S. and Canada Diabetes Care, July 1, 2002; 25(7): 1149 - 1153. [Abstract] [Full Text] [PDF]

				M. I. Harris Frequency of Blood Glucose Monitoring in Relation to Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, June 1, 2001; 24(6): 979 - 982. [Abstract] [Full Text]

				A. K. Maniatis, G. J. Klingensmith, R. H. Slover, C. J. Mowry, and H. P. Chase Continuous Subcutaneous Insulin Infusion Therapy for Children and Adolescents: An Option for Routine Diabetes Care Pediatrics, February 1, 2001; 107(2): 351 - 356. [Abstract] [Full Text]

				E. H. Wagner, N. Sandhu, K. M. Newton, D. K. McCulloch, S. D. Ramsey, and L. C. Grothaus Effect of Improved Glycemic Control on Health Care Costs and Utilization JAMA, January 10, 2001; 285(2): 182 - 189. [Abstract] [Full Text] [PDF]

				S. A. Grover, L. Coupal, H. Zowall, C. M. Alexander, T. W. Weiss, and D. R.J. Gomes How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease? Diabetes Care, January 1, 2001; 24(1): 45 - 50. [Abstract] [Full Text]

				S. A. Grover, L. Coupal, H. Zowall, and M. Dorais Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated? Circulation, August 15, 2000; 102(7): 722 - 727. [Abstract] [Full Text] [PDF]

				D. Young-Hyman Provider Impact in Diabetes Education: What We Know, What We Would Like to Know, Paradigms for Asking The Diabetes Educator, November 1, 1999; 25(6_suppl): 34 - 42. [Abstract] [PDF]

				The CDC Diabetes Cost-Effectiveness Study Group The Cost-effectiveness of Screening for Type 2 Diabetes JAMA, November 25, 1998; 280(20): 1757 - 1763. [Abstract] [Full Text] [PDF]

				M. A. Testa and D. C. Simonson Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial JAMA, November 4, 1998; 280(17): 1490 - 1496. [Abstract] [Full Text] [PDF]

				R. J. Rubin, K. A. Dietrich, and A. D. Hawk Clinical and Economic Impact of Implementing a Comprehensive Diabetes Management Program in Managed Care J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2635 - 2642. [Abstract] [Full Text]

				ADVERSE EFFECTS AND COSTS OF INTENSIVE INSULIN THERAPY Journal Watch (General), November 10, 1995; 1995(1110): 1 - 1. [Full Text]